[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:
10.1177/1060028018797110[2] ROBERTO PELLICCIARI. 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity[J]. Journal of Medicinal Chemistry, 2002, 45 17: 3569-3572. DOI:
10.1021/jm025529g[3] STEFANO FIORUCCI. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.[J]. Journal of Pharmacology and Experimental Therapeutics, 2005, 313 2: 604-612. DOI:
10.1124/jpet.104.079665[4] STEFANO FIORUCCI. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.[J]. ACS Applied Electronic Materials, 2005: 584-595. DOI:
10.1124/jpet.105.084905[5] GIOVANNI RIZZO. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.[J]. Molecular Pharmacology, 2006, 70 4: 1164-1173. DOI:
10.1124/mol.106.023820[6] SHINOBU MIYAZAKI-ANZAI. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.[J]. Circulation research, 2010, 106 12: 1807-1817. DOI:
10.1161/circresaha.109.212969
![Obeticholic Acid-[d4] Structure](/CAS/20211123/GIF/2025364-15-0.gif)